World Congress on Vaccines				
July 10-11, 2025 @ Vienna, Austria				
Day-1 (July 10, 2025)				
8:30-09:20 Registrations				
09:20-09:30	Welcome Remarks by Moderator			
Moderator: Júlia Vergara-Alert, Institute of Agrifood Research and Technology, Spain				
Keynote Talks				
Liang Zhou, University of Florida, USA	09:30-10:00	The role of Innate Lymphoid Cells in Mucosal Infection		
<b>Monica Lahra,</b> NSW Health Pathology, Australia	10:00-10:30	Multidrug resistant N. gonorrhoeae		
<b>Ying Liao</b> , Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, China	10:30-11:00	Coronavirus Nucleocapsid Protein Enhances p-PKCα Binding to RACK1: Implications for Inhibition of Nucleocytoplasmic Trafficking and Suppression of the Innate Immune Response		
Group Photo & Refreshment Break (11:00-11:20)				
Technical Session-I				
Session Chair : Liang Zhou, University of Florida, USA				
Jooeun Bae, Harvard Medical School, USA	11:20-11:40	Combinational Immunotherapy with Multi-antigen targeting Cancer Vaccine		
<b>Tian Wang,</b> University of Texas Medical Branch, USA	11:40-12:00	Development of safe and efficacious vaccines against emerging arboviruses		
<b>Lina Souan,</b> King Hussein Cancer Center, Jordan	12:00-12:20	Effectiveness and Duration of Anti-RBD SARS-CoV-2 IgG Response Across Vaccines: Implications for Vaccine Strategies		
Shin, Yeun-Kyung, Animal and Plant Quarantine Agency, South Korea	12:20-12:40	Propagation of porcine reproductive and respiratory syndrome virus increases in PRRSV-susceptible porcine kidney cells modifying LGP2 and RIG-I		
<b>Balázs Rada</b> , The University of Georgia, USA	12:40-13:00	Opportunities for targeting neutrophils to increase vaccine efficacy		
Lunch Break @ Restaurant (13:00-14:00)				
Technical Session-II				
Session Chairs: Monica Lahra, NSW Health Pathology, Australia				
<b>Maja Mockenhaupt</b> , University of Freiburg, Germany	14:00-14:20	Infections as possible trigger of epidermal necrolysis		
<b>Jerina Jaho,</b> University "Ismail Qemali" Vlore, Albania	14:20-14:40	Patients with HIV and Hepatitis B co-infection present special requirements for their management		
Polona Kogovšek, National institute of biology, Slovenia	14:40-15:00	Evaluation of the antiviral activity of compounds using computational, bioassay, molecular biology and electron microscopy techniques		
Emmanuel Mintah Bonku, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China	15:00-15:20	Progress in antiviral drug R&D via industrial-grade "control from root design" concept		
Refreshment Break (15:00-15:20)				
Ximeng Han, University of Oxford, United Kingdom	15:20-15:40	Preclinical Development of an Enhanced-Immunogenicity Pfs230-Pfs25 Malaria Transmission- Blocking Vaccine		
Luca Del Sorbo, University of Naples Federico II, Italy	15:40-16:00	Antiviral activity of fungal secondary metabolites dummyagainst bovine coronavirus infection		
Filomena Fiorito, University of Naples Federico II, Italy	16:00-16:20	Potential antiviral action of funicone-like compounds towards canine coronavirus infection		
Hamsa Taher Tayeb, King Faisal Specialist Hospital & Research Center, Saudi Arabia	16:20-16:40	Implementation of Next Generation Sequencing (NGS) as a Diagnostic Tool in Infectious Diseases		
		Pannol Discussions		

**Pannel Discussions** 

Day-2 (July 11, 2025)				
Moderator: Tian Wang, University of Texas Medical Branch, USA				
Keynote Talks				
Jerald Sadoff, Centivax Inc, USA	09:30-10:00	Universal vaccines against influenza and other pathogens		
<b>Taijiao Jiang</b> , Guangzhou National Laboratory, China	10:00-10:30	Modeling influenza antigenic evolution for vaccination by PREDAC		
Xiufen Zheng, Western University, Canada	10:30-11:00	Potentials and challenges of circular RNA as a therapy/vaccine in treating diseases		
Refreshment Break (11:00-11:20)				
Technical Session-III				
Session Chair: Xiufen Zheng, Western University, Canada				
<b>Yoon-Hee Lee</b> , Animal and Plant Quarantine Agency, South Korea	11:20-11:40	The appication of Nano-Luciferase based biosensor for the detection of FMDV(Foot and Mouth Disease Virus) type Asia1		
Ximeng Han, Jenner Institute, University of Oxford, UK	11:40-12:00	Preclinical Development of an Enhanced-Immunogenicity Pfs230-Pfs25 Malaria Transmission- Blocking Vaccine		
<b>João Luis Garcia,</b> Londrina State University, Spain	12:00-12:20	Vaccines against Toxoplasma gondii: the past, the present and the future		
<b>Júlia Vergara-Alert</b> , Institute of Agrifood Research and Technology, Spain	12:20-12:40	Discovery of an inhibitor ligand of IFNAR1: a new mechanism for viruses to escape from cellular innate immunity		
I Y Saleem, Liverpool John Moores University, UK	12:40-13:00	Inhalable Nanovaccine Targeting Pneumococcal Proteins for Lung Protection		
	Lunch	Break @ Restaurant (13:00-14:00)		
Technical Session-IV				
Session Chairs: TBA				
<b>Huanling Wu,</b> Shandong First Medical University, China	14:00-14:20	Platelet-to-lymphocyte ratio and absolute monocyte count have prognostic potential in primary myelodysplastic neoplasms		
Lorrin Pang, Hawaii Dept of Health, USA	14:20-14:40	Accurately monitoring the effect of intervention tools during a pandemic (fixing the plane while its flying).		
Sina Bavari, Tonix Pharmaceuticals Holding Corp, USA	14:40-15:00	TNX-801, a single-dose live vaccine platform for Mpox and other emerging viral diseases Safety, Immunogenicity, and Efficacy		
Pooja Goel, The Lyndhurst Surgery, UK	15:00-15:20	Barriers to the Flu Vaccination: Patients' Perspective within a London GP		
Baek Kim, Vernagen LLC, USA	15:20-15:40	Immunogenicity and protective efficacy of Respiratory Syncytial Virus mRNA vaccine encoding the F protein of both RSV subtypes A and B in a BALB/c mouse model		
Refreshment Break (15:40-16:00)				
Poster Presentations(16:00-16:30)				
Award Ceremony				
Day 2 Concludes				
NOTE: This is Tentative program and subject to change				
For more information, Contact @ <u>ryan_cooper@vaccine-congress.org</u>				